FluoroPharma Medical is a biopharmaceutical company focused on the discovery, development and commercialization of molecular imaging pharmaceuticals with primary applications in the area of cardiology in the U.S. The company’s products include BFPET, an imaging agent that has completed phase IA clinical trials in stress-testing for patients with known or suspected coronary artery disease (CAD) and CardioPET, a molecular imaging agent, which is in phase 2 clinical trials to assess myocardial metabolism for patients with CAD. For more information, visit the company’s website at www.fluoropharma.com